) has commenced a new study to evaluate the efficacy of its
BioFlo Peripherally Inserted Central Catheter (PICC) in reducing
catheter-related thrombosis. This should boost investor
confidence and help to maintain the positive trend demonstrated
by the company's stock over the last one month.
ANGIODYNAMICS (ANGO): Free Stock Analysis
BARD C R INC (BCR): Free Stock Analysis
LUMINEX CORP (LMNX): Free Stock Analysis
MASIMO CORP (MASI): Free Stock Analysis
To read this article on Zacks.com click here.
ANGO has enrolled its first patient under the "PICC Related
Obstruction of Flow" (PROOF) randomized multi-center study at
University of Miami Hospital. The study intends to enroll 354
patients at a maximum of five sites, including University of
Miami Hospital, NorthShore University HealthSystem of Chicago and
Ottawa Hospital Research Institute, Canada.
BioFlo is the only power injectable PICC available that uses an
integrated Endexo Technology. BioFlo's long-term durability and
efficacy is intended to provide clinicians a high degree of
safety and confidence in providing better patient care and
improved patient outcomes.
As part of the study, the cost-efficiency of AngioDynamics'
BioFlo PICC will be compared with
) PowerPICC SOLO2, a commercially available PICC. In addition to
analyzing the incidence of catheter-related venous thrombosis,
the study will also evaluate the occurrence of catheter-related
It has been proved that on an average, BioFlo PICC has 87% lesser
thrombus accumulation on its surface in an in-vitro blood loop
model test in comparison to commonly used PICCs, based on
platelet count. Moreover, side-by-side in vivo test results also
substantiate the benefits of BioFlo PICC.
The latest PROOF trial has been initiated to clinically validate
the fact that BioFlo PICC is the best product available in the
market. Successful completion of the trial should bolster
revenues of ANGO's beleaguered Vascular division. In the last
reported quarter, revenues from this division declined 4%.
AngioDynamics should continue to benefit from the ongoing shift
from open surgery to less-invasive interventional procedures.
Despite the near-term operational glitches, the company has the
ability to grow in the long term, on the back of higher
international sales, new products, acquisitions, and operational
synergies from its cost-saving measures.
Currently, AngioDynamics has a Zacks Rank #3 (Hold). While we
remain on the sidelines regarding ANGO, medical stocks such as
) are worth considering. Both these stocks have a Zacks Rank #2